Recent Updates — IART
Integra LifeSciences reported third-quarter revenues of $411.2 million, a 2.5% organic increase, with adjusted earnings per diluted share of $0.59 compared to $0.54 in the prior year period. The company also announced it completed a $2.1 billion debt refinancing on October 19, consisting of a new senior secured credit facility and $450 million in 9.5% senior secured notes due 2033, which extended maturities and enhanced financial flexibility. Full-year revenue guidance remains at $1.634 billion to $1.654 billion with adjusted EPS expected between $2.30 and $2.40. Integra LifeSciences is a global medical technology company focused on neurosurgery and tissue reconstruction products.
Integra LifeSciences Holdings Corporation completed a private offering of $450 million in aggregate principal amount of 9.500% Senior Secured Notes due November 2033. Concurrently, the company entered into an amended and restated credit agreement providing up to $1.65 billion in financing, consisting of a $600 million senior secured revolving facility, a $600 million Term Loan A facility, and a $450 million Term Loan B facility. The company utilized proceeds from the notes and borrowings under the new credit facility to repay its existing $1.3 billion revolving credit facility and $775 million term loan facility in full. Integra LifeSciences is a global medical technology leader focused on neurosurgery and tissue reconstruction.
Integra LifeSciences Holdings Corporation priced $450 million aggregate principal amount of 9.500% senior secured notes due 2033 in a private placement. The notes are general senior secured obligations guaranteed by wholly-owned domestic subsidiaries and are expected to close on or about October 19, 2026. Proceeds will be used to refinance existing credit facilities and pay related fees as part of a broader refinancing transaction. Management anticipates the effective interest rate will increase near the high end of the previously communicated 100-200 basis points range. Integra LifeSciences is a global medical technology leader focused on neurosurgery and tissue reconstruction.
Integra LifeSciences Holdings Corporation announced preliminary unaudited results for the third quarter ended September 30, 2026, and updated its full-year guidance. The company expects Q3 revenue of $410 million to $412 million and adjusted diluted EPS of $0.55 to $0.59, reflecting a $7 million negative impact from flooding-related supply disruptions at its Cincinnati manufacturing facility. Full-year 2026 reported revenue guidance was lowered to $1.634 billion–$1.654 billion (from $1.654 billion–$1.695 billion), and adjusted diluted EPS guidance was reduced to $2.30–$2.40 (from $2.40–$2.50). The company anticipates Q3 operating cash flow exceeding $85 million and full-year operating cash flow of approximately $190 million to $200 million. Integra expects a return to full manufacturing operations at the Cincinnati facility in the second quarter of 2027, with insurance recoveries expected to mitigate a substantial portion of the earnings impact. Integra LifeSciences is a global medical technology company specializing in neurosurgery and tissue reconstruction products.
Integra LifeSciences Holdings Corp filed an updated investor presentation on September 8, 2026, intended for use with prospective lenders as the company plans to refinance its outstanding senior credit facility in 2026. The presentation highlights trailing twelve-month revenue of $1.6 billion and adjusted EBITDA of $337 million, representing a 20.5% margin. Key operational milestones include the Q2 2026 activation of a new Braintree, Massachusetts manufacturing site and an anticipated Q4 2026 relaunch of the SurgiMend product. The company reports net leverage has decreased to 4.1x from 4.5x at year-end 2025, with a target range of 2.5x to 3.5x. Integra LifeSciences Holdings Corp operates in the medical device industry, specializing in neurosurgery and regenerative tissue repair solutions.
Integra LifeSciences Holdings Corporation reported second quarter 2026 financial results on July 29, 2026. Total revenues were $418.8 million, a 0.8% increase from the prior year period. GAAP net income was $4.5 million, or $0.06 per diluted share, compared to a loss of $(484.1) million in the previous year. Adjusted earnings per diluted share were $0.56, up from $0.45. The company updated its full-year reported revenue guidance to $1.654 billion–$1.695 billion and reaffirmed adjusted EPS guidance of $2.40–$2.50. Net debt stood at $1.6 billion with a leverage ratio of 4.1x. Integra operates in the medical technology industry, specializing in neurosurgery and tissue reconstruction products.